Top

Published in:

01-01-2017 | Topic Review

Withaferin A and its potential role in glioblastoma (GBM)

Authors: Jasdeep Dhami, Edwin Chang, Sanjiv S. Gambhir

Published in: Journal of Neuro-Oncology | Issue 2/2017

Abstract

Within the Ayurvedic medical tradition of India, Ashwagandha (Withania somnifera) is a well-known herb. A large number of withanolides have been isolated from both its roots and its leaves and many have been assessed for their pharmacological activities. Amongst them, Withaferin A is one of its most bioactive phytoconstituents. Due to the lactonal steroid’s potential to modulate multiple oncogenic pathways, Withaferin A has gained much attention as a possible anti-neoplastic agent. This review focuses on the use of Withaferin A alone, or in combination with other treatments, as a newer option for therapy against the most aggressive variant of brain tumors, Glioblastoma. We survey the various studies that delineate Withaferin A’s anticancer mechanisms, its toxicity profiles, its pharmacokinetics and pharmacodynamics and its immuno-modulating properties.

Available only for authorised users

Patel K, Singh RB, Patel DK (2013) Pharmacological and analytical aspects of Withaferin A: a concise report of current scientific literature. Asian Pac J Reprod 2:238–243. doi:10.1016/S2305-0500(13)60154-2 CrossRef

Singh N, Bhalla M, De Jager P, Gilca M (2011) An overview on ashwagandha: a rasayana (rejuvenator) of ayurveda. Afr J Tradit Complement Altern Med. doi:10.4314/ajtcam.v8i5S.9

Alam N, Hossain M, Khalil MI et al (2011) Recent advances in elucidating the biological properties of Withania somnifera and its potential role in health benefits. Phytochem Rev 11:97–112. doi:10.1007/s11101-011-9221-5 CrossRef

Tiwari R, Chakraborty S, Saminathan M et al (2014) Ashwagandha (Withania somnifera): role in safeguarding health, immunomodulatory effects, combating infections and therapeutic application: a review. J Biol Sci 2:77–94

Khan S, Malik F, Suri KA, Singh J (2009) Molecular insight into the immune up-regulatory properties of the leaf extract of Ashwagandha and identification of Th1 immunostimulatory chemical entity. Vaccine 27:6080–6087. doi:10.1016/j.vaccine.2009.07.011 CrossRefPubMed

Kurup PA (1956) Antibiotic principle of the leaves of Withania somnifera. Curr Sci 25:57

Kurup PA (1958) The antibacterial principle of Withania somnifera. I. Isolation and antibacterial activity. Antibiot Chemother 8:511

Devi PU (2014) Withania somnifera Dunal (Ashwagandha):Potential plant source of a promising dug for cancer chemotherapy and radiosensitization. Indian J Exp Biol 34:927–932

Lavie D, Glotter E, Shvo Y (1965) Constituents of Withania somnifera Dun. Part IV. The structure of withaferin A. J Chem Soc Resumed 7517. doi:10.1039/jr9650007517

10.

Shohat B, Gitter S, Abraham A, Lavie D (1967) Antitumor activity of Withaferin A (NSC-101088). Cancer Chemother Rep 51:1–6

11.

Budhiraja RD, Krishan P, Sudhir S (2000) Biological activity of Withanolides. J Sci Ind Res 59:904–911

12.

Fuska J, Prokska B, Williamson J (1987) Microbiological and chemical dehydrogenation of Withaferin A. Folia Microbiol (Praha) 32:112–115CrossRef

13.

Fuska J, Khadlova A, Sturdikova M et al (1985) Biotransformation of Withaferin-A by a culture of arthrobacter simplex. Folia Microbiol 30:427–432CrossRef

14.

Fuska J, Fuskova A, Rosazza P (1984) Novel cytotoxic and antitumor agents.IV. Withaferin A: relation of its structure to the in vitro cytotoxic effects on P388 cells. Neoplasma 31(1):31–36PubMed

15.

Santagata S, Xu Y, Wijeratne EMK et al (2012) Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol 7:340–349. doi:10.1021/cb200353m CrossRefPubMed

16.

Berghe WV, Sabbe L, Kaileh M et al (2012) Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol 84:1282–1291. doi:10.1016/j.bcp.2012.08.027 CrossRef

17.

Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68:3033–3046CrossRefPubMedPubMedCentral

18.

Bargagna-Mohan P, Hamza A, Kim Y et al (2007) The tumor inhibitor and antiangiogenic agent Withaferin A targets the intermediate filament protein vimentin. Chem Biol 14:623–634. doi:10.1016/j.chembiol.2007.04.010 CrossRefPubMedPubMedCentral

19.

Caplan JF, Filipenko NR, Fitzpatrick SL, Waisman DM (2004) Regulation of annexin A2 by reversible glutathionylation. J Biol Chem 279:7740–7750. doi:10.1074/jbc.M313049200 CrossRefPubMed

20.

Yokota Y, Bargagna-Mohan P, Ravindranath PP et al (2006) Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett 16:2603–2607. doi:10.1016/j.bmcl.2006.02.039 CrossRefPubMedPubMedCentral

21.

Mohan R, Hammers H, Bargagna-Mohan P, Zhan X (2004) Withaferin A is a potent inhibitor or angiogenesis. Angiogenesis 115–22.

22.

Yang H, Shi G, Dou QP (2006) The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from “Indian winter cherry”. Mol Pharmacol 71:426–437. doi:10.1124/mol.106.030015 CrossRefPubMed

23.

Grover A, Shandilya A, Punetha A et al (2010) Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera’s key metabolite Withaferin A. BMC Genomics 11:S25. doi:10.1186/1471-2164-11-S4-S25 CrossRefPubMedPubMedCentral

24.

Kaileh M, Berghe WV, Heyerick A (2007) Withaferin A strongly elicits IB kinase hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 282:4253–4264. doi:10.1074/jbc.M606728200 CrossRefPubMed

25.

Bernier M (2006) Binding of manumycin A inhibits IkappaB kinase beta activity. J Biol Chem 281:2551–2561. doi:10.1074/jbc.M511878200 CrossRefPubMed

26.

Gupta S, Reuter S, Kannappan R, Yadav V (2010) Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents. J Biol Chem 285:35406–35417. doi:10.1074/jbc.M110.161984 CrossRefPubMedPubMedCentral

27.

Kim BH, Lee J-Y, Seo JH et al (2007) Artemisolide is a typical inhibitor of IκB kinase β targeting cysteine-179 residue and down-regulates NF-κB-dependent TNF-α expression in LPS-activated macrophages. Biochem Biophys Res Commun 361:593–598. doi:10.1016/j.bbrc.2007.07.069 CrossRefPubMed

28.

Liang M-C, Bardhan S, Pace EA et al (2006) Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity. Biochem Pharmacol 71:634–645. doi:10.1016/j.bcp.2005.11.013 CrossRefPubMed

29.

Palempalli UD, Gandhi U, Kalantari P et al (2009) Gambogic acid covalently modifies IκB kinase-β subunit to mediate suppression of lipopolysaccharide-induced activation of NF-κB in macrophages. Biochem J 419:401. doi:10.1042/BJ20081482 CrossRefPubMedPubMedCentral

30.

Sen N, Banerjee B, Das B, Ganguly A (2007) Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. Cell Death Differ 14:358–367. doi:10.1038/sj.cdd.4402002 CrossRefPubMed

31.

Grover A, Shandilya A, Agrawal V et al (2011) Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors. Biochem Biophys Res Commun 404:498–503. doi:10.1016/j.bbrc.2010.12.010 CrossRefPubMed

32.

Grover A, Shandilya A, Agrawal V et al (2011) Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics 12:S30. doi:10.1186/1471-2105-12-S1-S30 CrossRefPubMedPubMedCentral

33.

Yu Y, Hamza A, Zhang T et al (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79:542–551. doi:10.1016/j.bcp.2009.09.017 CrossRefPubMedPubMedCentral

34.

Mendillo ML, Santagata S, Koeva M, al et (2013) HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. PubMed Cent 150:549–562. doi:10.1016/j.cell.2012.06.031

35.

Zou J, Guo Y, Guettouche T et al (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94:471–480CrossRefPubMed

36.

Mehrotra A, Kaul D, Joshi K (2010) LXR-α selectively reprogrammes cancer cells to enter into apoptosis. Mol Cell Biochem 349:41–55. doi:10.1007/s11010-010-0659-3 CrossRefPubMed

37.

Min K, Choi K, Kwon TK (2011) Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells. Int Immunopharmacol 11:1137–1142. doi:10.1016/j.intimp.2011.02.029 CrossRefPubMed

38.

Munagala R, Kausar H, Munjal C, Gupta RC (2011) Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 32:1697–1705. doi:10.1093/carcin/bgr192 CrossRefPubMed

39.

Koduru S, Kumar R, Srinivasan S et al (2010) Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 9:202–210. doi:10.1158/1535-7163.MCT-09-0771 CrossRefPubMedPubMedCentral

40.

Ndlovu MN, Van Lint C, Van Wesemael K et al (2009) Hyperactivated NF-kappaB and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol 29:5488–5504. doi:10.1128/MCB.01657-08 CrossRefPubMed

41.

Stan SD, Hahm ER, Warin R, Singh SV (2008) Withaferin A causes foxo3a- and bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 68:7661–7669. doi:10.1158/0008-5472.CAN-08-1510 CrossRefPubMedPubMedCentral

42.

Widodo N, Kaur K, Shrestha BG et al (2007) Selective killing of cancer cells by leaf extract of ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clin Cancer Res 13:2298–2306. doi:10.1158/1078-0432.CCR-06-0948 CrossRefPubMed

43.

Kataria H, Shah N, Kaul SC et al (2011) Water extract of ashwagandha leaves limits proliferation and migration, and induces differentiation in glioma cells. Evid Based Complement Alternat Med 2011:1–12. doi:10.1093/ecam/nep188 CrossRef

44.

Thaiparambil JT, Bender L, Ganesh T et al (2011) Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer 129:2744–2755. doi:10.1002/ijc.25938 CrossRefPubMed

45.

Patil D, Gautam M, Mishra S et al (2013) Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. J Pharm Biomed Anal 80:203–212. doi:10.1016/j.jpba.2013.03.001 CrossRefPubMed

46.

Gupta RC, Bansal SS, Aqil F et al (2012) Controlled-release systemic delivery—a new concept in cancer chemoprevention. Carcinogenesis 33(8):1608–1615. doi:10.1093/carcin/bgs209 CrossRefPubMedPubMedCentral

47.

Rosazza JP, Nicholas AW, Gustafson ME. (1978) Microbial transformations of natural antitumor agents. 7. 14-alpha-Hydroxylation of withaferin-A by Cunninghamella elegans (NRRL 1393). Steroids 31(5):671–679. doi:10.1016/S0039-128X(78)80007-5 CrossRefPubMed

48.

Gorgan PT (2014) Withaferin A: a novel therapeutic approach for malignant brain tumors. KU ScholarWorks 33(5):1462–1476

49.

Panda S, Kar A (1998) Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. J PharmPharmacol 50:1065–1068

50.

Kupchan (1965) Isolation of Withaferin A. J Am Chem Soc 87(24):5805–5806CrossRefPubMed

51.

McFarland BC, Hong SW, Rajbhandari R et al (2013) NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One 8:e78728. doi:10.1371/journal.pone.0078728 CrossRefPubMedPubMedCentral

52.

Grogan PT, Sarkaria JN, Timmermann BN, Cohen MS (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604–617. doi:10.1007/s10637-014-0084-7 CrossRefPubMedPubMedCentral

53.

Shah N, Kataria H, Kaul SC et al (2009) Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation, migration, and differentiation of glioblastoma cells: Combinational approach for enhanced differentiation. Cancer Sci 100:1740–1747. doi:10.1111/j.1349-7006.2009.01236.x CrossRefPubMed

54.

Grogan PT, Sleder KD, Stecklein SR, Cohen MS (2011) Vassobia breviflora root-extract withaferin a as a novel cytotoxic and synergistic agent against malignant gliomas. J Surg Res 165:311. doi:10.1016/j.jss.2010.11.352 CrossRef

55.

Grogan P, Samadi AK, Cohen MS (2010) A novel cytotoxic agent induces apoptosis in malignant gliomas in vitro. J Surg Res 158:341–342. doi:10.1016/j.jss.2009.11.468 CrossRef

56.

Zhang B, Shah S, Prince J et al (2014) The antitumor effects of Withaferin A in glioblastoma stem cells. Neuro Oncol 16:v79–v95. doi:10.1093/neuonc/nou255

57.

Chang E, Pohling C, Natarajan A et al (2016) AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models. J Neurooncol 126:253–264. doi:10.1007/s11060-015-1972-1 CrossRefPubMed

58.

Grogan PT, Sleder KD, Samadi AK et al (2012) Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs 31:545–557. doi:10.1007/s10637-012-9888-5 CrossRefPubMedPubMedCentral

59.

Palyi I, Tyihak E, Palyi V (2015) Cytological effects of compounds isolated from Withania Somnifera Dun. Herba Hung 8:73–78

60.

Batia S, Gitter S, Lavie D (1970) Effect of Withaferin on Ehrlich carcinoma-cytological observation. Int J Cancer 5(2):244–252CrossRef

61.

Shohat B, Joshua H (1971) Effect of Withaferin A on ehrilch ascites tumor cells II. target tumor cell destruction in vivo by immune activation. Int J Cancer 8:487–496. doi:10.1002/ijc.2910080317 CrossRefPubMed

62.

Shohat B (1973) Effect of Withaferin A on cells in tissue culture. ZKrebsforsch 80:97–102CrossRef

63.

Yoshida M, Hoshi A, Kuretani K (1979) Relationship between chemical structure and antitumor activity of Withaferin A analogues. J Pharm Dyn 2:92–97CrossRef

64.

Begum VH, Sadique J (1987) Effect of Withania somnifera on glycosaminoglycan synthesis in carrageenin-induced AiR pouch granuloma. Biochem Med Metab Biol 38:272–277CrossRefPubMed

65.

Devi PU, Sharada AC, Solomon FE (1993) Antitumor and Radiosensitizing effect of Withania somnifera (Ashwagandha) on a transplantable mouse tumor, Sarcoma-180. Indian J Exp Biol 31:607–611PubMed

66.

Devi PU, Sharada AC, Solomon FE (1995) In vivo growth inhibitory and radiosensitizing effects of Withaferin A on mouse Ehrlich ascites carcinoma. Cancer Lett 95:189–193CrossRefPubMed

67.

Sharada AC, Solomon FE (1996) Antitumor and radiosensitizing effect of Withania A on mouse ehrlich ascities carcinoma in vivo. Acta Oncol 35:95–100CrossRefPubMed

68.

Devi PU (1996) Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Indian J Exp Biol 34(10):927–932PubMed

69.

Devi PU, Akagi K, Ostapenko V, al et (2003) Withaferin A: a new radiosensitizer from the Indian medicinal plant Withania somnifera. Int J Radiat Biol 69:193–197CrossRef

70.

Devi PU, Kamath R (2003) Radiosensitizing effect of Withaferin A combined with hyperthermia on mouse fibrosarcoma and melanoma. J Radiat Res 44:1–6CrossRef

71.

Mandal C, Dutta A, Mallick A et al (2008) Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 13:1450–1464. doi:10.1007/s10495-008-0271-0 CrossRefPubMed

72.

Widodo N, Shah N, Priyandoko D et al (2009) Deceleration of senescence in normal human fibroblasts by withanone extracted from ashwagandha leaves. J Gerontol A Biol Sci Med Sci 64:1031–1038. doi:10.1093/gerona/glp088 CrossRefPubMed

73.

Samadi A, Loo P, Mukerji R et al (2009) A novel HSP90 modulator with selective activity against thyroid cancers in vitro. Surgery 146:1196–1207. doi:10.1016/j.surg.2009.09.028 CrossRefPubMedPubMedCentral

74.

Devi PU, Sharada AC, Solomon FE, Kamath MS (1992) In vivo growth inhibitory effect of Withania Somnifera (Ashwagandha) on a transplantable mouse model, Sarcoma 180. Indian J Exp Biol 30:169–172PubMed

75.

Shohat B, Kirson I, Lavie D (1978) Immunosuppressive activity of two plant steroidal lactones withaferin A and withanolide. Biomedicine 28(1):18–24PubMed

76.

Rasool M, Varalakshmi P (2006) Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: an in vivo and in vitro study. Vascul Pharmacol 44:406–410. doi:10.1016/j.vph.2006.01.015 CrossRefPubMed

77.

Davis L, Kuttan G (2000) Immunomodulatory activity of Withania. J Ethnopharmacol 71:193–200CrossRefPubMed

78.

Verma SK, Shaban A, Purohit R et al (2012) Immunomodulatory activity of Withania somnifera (L.). J Chem Pharm Res 4:559–561

79.

Bani S, Gautam M, Sheikh FA et al (2006) Selective Th1 up-regulating activity of Withania somnifera aqueous extract in an experimental system using flow cytometry. J Ethnopharmacol 107:107–115. doi:10.1016/j.jep.2006.02.016 CrossRefPubMed

80.

Malik F, Singh J, Khajuria A et al (2007) A standardized root extract of Withania somnifera and its major constituent withanolide A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. Life Sci 80:1525–1538. doi:10.1016/j.lfs.2007.01.029 CrossRefPubMed

81.

Malik F, Kumar A, Bhushan S et al (2009) Immune modulation and apoptosis induction: two sides of antitumoural activity of a standardized herbal formulation of Withania somnifera. Eur J Cancer 45:1494–1509. doi:10.1016/j.ejca.2009.01.034 CrossRefPubMed

82.

Sharada AC, Solomon FE, Devi PU (1993) Toxicity of Withania somnifera root extract in rats and mice. Int J Pharmacog 3:205–212CrossRef

83.

Raut A, Rege N, Shirolkar S et al (2012) Exploratory study to evaluate tolerability, safety, and activity of Ashwagandha (Withania somnifera) in healthy volunteers. J Ayurveda Integr Med 3:111. doi:10.4103/0975-9476.100168 CrossRefPubMedPubMedCentral

84.

Sehgal VN, Verma P, bhattacharya SN (2014) fixed drug eruption caused by ashwagandha (Wihania somnifera):a widely used ayurvedic drug. Case Study 10:48–49.

85.

Toniolo M, Ceschi A et al (2011) Haemolytic anaemia and abdominal pain—a cause not to be missed. Br J Clin Pharmacol 1–2. doi:10.1111/j.1365-2125.2011.03909.x PubMedPubMedCentral

Title: Withaferin A and its potential role in glioblastoma (GBM)
Authors: Jasdeep Dhami
Edwin Chang
Sanjiv S. Gambhir
Publication date: 01-01-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2303-x

At a glance: The STEP trials

Springer Medicine

Withaferin A and its potential role in glioblastoma (GBM)

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

DTI fiber tractography of cerebro-cerebellar pathways and clinical evaluation of ataxia in childhood posterior fossa tumor survivors

Factors affecting survival outcomes of patients with non-metastatic Ewing’s sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center

Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status

Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study

Intra-rater variability in low-grade glioma segmentation